Abstract Although little evidence supports cannabis-induced amotivational syndrome, sources continue to assert that the drug saps motivation 1, which may guide current prohibitions. Few studies report low motivation in…
Condition: Mental Disorders
Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis
Abstract Rationale: Stress is a risk factor for psychosis and treatments which mitigate its harmful effects are needed. Cannabidiol (CBD) has antipsychotic and anxiolytic effects. Objectives: We investigated whether CBD…
Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users
Abstract Introduction: Chronic cannabis use has been associated with impaired cognition and elevated psychological symptoms, particularly psychotic-like experiences. While D9-tetrahydrocannabinol (THC) is thought to be primarily responsible for these deleterious…
The therapeutic role of Cannabidiol in mental health: a systematic review
Abstract Background: The therapeutic application of cannabidiol (CBD) is gaining interest due to expanding evidence for its use. Objective: To summarize the clinical outcomes, study designs and limitations for the…
Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age
Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a compound that does not produce the typical subjective effects of marijuana. Objectives: The aim of the present review…
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Cannabidiol is a component of marijuana that does not activate cannabinoid receptors, but moderately inhibits the degradation of the endocannabinoid anandamide. We previously reported that an elevation of anandamide levels…
Cannabinoid CB1 receptors in the dorsal hippocampus and prelimbic medial prefrontal cortex modulate anxiety-like behavior in rats: Additional evidence
Endocannabinoids (ECBs) such as anandamide (AEA) act by activating cannabinoid type 1 (CB1) or 2 (CB2) receptors. The anxiolytic effect of drugs that facilitate ECB effects is associated with increase…
β-Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice
Recent evidence suggests that the cannabinoid receptor subtype 2 (CB2) is implicated in anxiety and depression disorders, although few systematic studies in laboratory animals have been reported. The aim of…
Therapeutical use of the cannabinoids in psychiatry
Objective: To review the main advances related to the potential therapeutic use of cannabinoid compounds in psychiatry. Method: A search was performed in the online databases PubMed, ScieELO, and Lilacs…